Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 982
countries
28
conditions
2 109

10 trials match your criteria

Epidermolysis bullosa

Recruiting

Study on the Effects of TCP-25 Gel for Wound Healing in Patients with Epidermolysis Bullosa

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH

Epidermolysis bullosa

Recruiting

Study on Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Using Skin Grafts with Genetically Corrected Autologous Keratinocytes and Fibroblasts

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS KERATINOCYTES AND FIBROBLASTS TRANSDUCED WITH A RETROVIRAL VECTOR ENCODING COL7A1 CDNA

Epidermolysis bullosa

Recruiting

Study on Diacerein 1% Ointment for Treating Generalized Epidermolysis Bullosa Simplex in Patients Aged 6 Months and Older

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Diacerein

Epidermolysis bullosa

Recruiting

Study on the Effectiveness and Safety of Apremilast for Patients Aged 6 and Older with Generalized Epidermolysis Bullosa Simplex

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apremilast

Epidermolysis bullosa

Recruiting

Study on the Effect of Cholestyramine on Pollutant Levels in Obese Women Eligible for Bariatric Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Colestyramine

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate

Epidermolysis bullosa

Not yet recruiting

Assessing the efficacy and safety of nemolizumab in patients aged 12 years or older with dystrophic epidermolysis bullosa

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab

Epidermolysis bullosa

Not recruiting

Study on Rigosertib Sodium for Patients with Recessive Dystrophic Epidermolysis Bullosa and Advanced Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rigosertib Sodium

Epidermolysis bullosa

Not recruiting

Study on the Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells for Patients with Epidermolysis Bullosa

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded

Epidermolysis bullosa+1

Not recruiting

Study on the Effects of Deucravacitinib for Adults with Inflammatory Skin Conditions (Epidermolysis Bullosa Simplex and Congenital Ichthyoses)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.